Atlas Trials

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Clinical trial NCT02414958 · COMPLETED

Trial details

NCT number
NCT02414958
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Diabetes Mellitus, Type 1
Start date
2015-06-30
Primary completion
2017-04-20
Enrollment
730

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.